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Determination of potassium level is one of the most frequent laboratory tests in clin-
ical medicine. Hyperkalaemia is deﬁned as a potassium level >5.0mmol/L and is one
of the most clinically important electrolyte abnormalities, because it may cause dan-
gerous cardiac arrhythmia and sudden cardiac death. Here, we review methodologi-
cal challenges in the determination of potassium levels, important clinical aspects of
the potassium homoeostasis as well as of the pathophysiology of hyperkalaemia.
Methodological challenges
Potassium level is usually determined in a venous blood
sample. However, inappropriate blood sampling technique
may affect the result. It may cause release of potassium
from working skeletal muscle cells and/or release of potas-
sium from cellular components of blood during or after
sampling. Thus, potassium blood sampling should primarily
be done following a few minutes of physical rest, because
potassium level rises during physical activity and is not nor-
malized before after a few minutes of rest. A large vein
should be used, e.g. the cubital vein, without fist clenching
and without prolonged application of a tourniquet. Only
needles, tubes, and tube adapters approved for potassium
measurements should be employed to minimize haemoly-
sis. Moreover, samples for measurement of potassium
should routinely be checked for haemolysis, and if an error
is suspected, measurement should be repeated with blood
sampled appropriately or eventually taken as an arterial
sample. In case of haemolysis, the clinician should consider
whether it occurred in vitro (in the test tube) or in vivo (in
the body). Pseudohyperkalaemia refers to potassium
>5mmol/L in the test tube and normal potassium level in
the body. It should be noted that in addition to causing
pseudohyperkalaemia, errors of potassium determination
may conceal hypokalaemia. Finally, potassium should not
be measured in an arm that is also used for liquid infusion,
because it may jeopardize the measurement. Thus, potas-
sium levels should be determined using a standardized set-
up ensuring high accuracy and precision.
Potassium levels were traditionally measured in serum
from coagulated blood, but are now more frequently mea-
sured in plasma from heparinized blood. Serum levels may
generally be 0.2–0.4mmol/L higher than plasma levels,
and up to 0.7mmol/L higher levels have been reported in
serum when compared with plasma. This is especially a
problem with high values. Thus, when shifting from serum
to plasmameasurements the reference range for potassium
level needs appropriate adjustment. This must be taken
into consideration by the clinician when changing from*Corresponding author. Tel: þ4540253784, Email: kjeldsen@rh.dk
Published on behalf of the European Society of Cardiology.VC The Author(s) 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any
medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
European Heart Journal Supplements (2019) 21 (Supplement A), A2–A5
The Heart of the Matter
doi:10.1093/eurheartj/suy033
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartjsupp/article-abstract/21/Supplem
ent_A/A2/5364192 by Faculty of Life Sciences Library user on 08 July 2019
serum based to plasma based measurements. And in any
scientific study on potassium levels it must be clarified,
whether it is plasma or serum that has been used for potas-
sium measurements. At present, it is confusing that
‘plasma potassium’ and ‘serum potassium’ are sometimes
considered synonyms. Moreover, it is distracting that levels
for normal potassium range, hyperkalaemia as well as
hypokalaemia may differ. Thus, there is at present a need
for international consensus on how to resolve and handle
these flaws. First, then it will become possible to pool po-
tassium levels from various hospitals, countries, and stud-
ies to clearly establish risks at various levels of hyper- and
hypokalaemia. In this paper, we mostly use the expression
‘potassium level’, because it is at present unclear in many
studies, what actually wasmeasured.
The reference interval for potassium at our hospital is
3.5–4.6mmol/L. Here, plasma potassium is measured.
However, different reference intervals may apply in other
settings. Hyperkalaemia may be defined as a potassium
level >5mmol/L and hypokalaemia as a potassium level
<3.5mmol/L, and indeed even other cut-off levels are
sometimes applied. It should be noted that whereas hypo-
kalaemia is defined as a potassium level below reference
level, hyperkalaemia is defined as a potassium level
0.4mmol/L above the reference level. Mild hyperkalaemia
may be defined as a potassium level >5.0–5.5mmol/L,
moderate hyperkalaemia as a level >5.5–6.0mmol/L, and
severe hyperkalaemia as a level >6.0mmol/L. For the cli-
nician this is not so important, because physicians must re-
act according to prevailing settings. However, for studies
compiling potassium data from various hospitals, coun-
tries, and studies these variations are challenging and may
blur the outcome significantly.1–4 Thus, also here there is a
need for international consensus.
Potassium homoeostasis
Potassium is the most abundant cation in the body. Daily
potassium intake is around 100mmol, and it mainly comes
from fruits, vegetables, andmeat.
Long-term regulation of potassium homoeostasis takes
place over hours to days and in healthy subjects depends
mainly on renal potassium excretion. Renal potassium han-
dling has been intensively reviewed recently—see Kovesdy
et al.5 The colon is responsible for a remaining few percent
of the potassium excretion, and the colon may in patients
with end stage renal disease increase faecal potassium se-
cretion. However, other tissues contribute to short-term
regulation of potassium homoeostasis, which takes place
over only seconds to minutes. Here, skeletal muscles play
an important role primarily because skeletal muscles con-
tain the largest single pool of potassium in the body. Thus,
for an adult human subject it has been calculated that the
potassium content of the total skeletal muscle pool is
approximately 225 times larger than the potassium
content in the extracellular phase. Moreover, due to the
large number of Na,K-pumps (sodium, potassium-
adenosinetriphosphatase) and potassium channels, the
skeletal muscles possess a huge capacity for potassium ex-
change. Hence, for an adult human subject it has been
calculated that if all potassium channels or all Na,K-pumps
were activated to maximum capacity for potassium leak-
age or uptake, respectively, the entire extracellular potas-
sium pool could be over flooded or cleared for potassium in
a matter of seconds to minutes. Thus, a close regulation of
skeletal muscle Na,K-pumps is essential, and takes place as
an up- or down-regulation of the activity of prevailing
Na,K-pumps or/and as an up- or down-regulation of the
number of Na,K-pumps.5,6
Physical exertion or exercise is a major challenge to
short-term potassium regulation. During exercise, skeletal
muscle loses potassium during repetitive action potentials.
Because skeletal muscles constitute the major reservoir for
potassium in the body, potassium level may increase mark-
edly and attain values up to around 8mmol/L that may be
sustained during exercise. Physical conditioning or training
has been found to reduce the increase in potassium during
exercise probably due to an increase in the number of
Na,K-pumps in skeletal muscles. Upon cessation of exer-
cise, recovering muscles regain lost potassium by Na,K-
pumpmediated potassium uptake. This leads to normaliza-
tion of potassium level within minutes, which may be pre-
ceded by a temporary undershoot of potassium level and
subsequent transient hypokalaemia (<3.5mmol/L). In ad-
dition, volume changes occur during these potassium level
changes. The important observation is however, that the
heart may be exposed to high potassium levels during exer-
cise and a major drop in potassium level at cessation of ex-
ercise. Also important is the observation that this drop
seems to be associated with impaired cardiac repolariza-
tion, which could potentially trigger arrhythmia and sud-
den cardiac death in susceptible individuals with pre-
existing hypokalaemia and/or heart disease such as ischae-
mic heart disease, heart failure, ventricular arrhythmia,
and inherited or acquired long QT-syndrome.7–9
The knowledge of potassium homoeostasis during exer-
cise and recovery has several implications: first, it
emphasizes the importance of appropriate rest before
blood sampling for determination of potassium level.
Second, it shows that mild tomoderate hyperkalaemia may
be a normal phenomenon that should not always be feared.
Third, to the normal range for resting potassium level a
normal range for exercise potassium level could be of use.
Fourth, in patients suspected to be prone to exercise in-
duced arrhythmia, an exercise test could be considered
during which monitoring of potassium level from rest, dur-
ing exercise, and recovery might yield information of
value. Fifth, exposure of the heart to extreme hyperkalae-
mia during exercise and/or extremely rapid lowering of po-
tassium level after exercise may cause arrhythmia and
sudden cardiac death in predisposed persons.
Pathophysiology of hyperkalaemia
Hyperkalaemia is one of the most clinically important elec-
trolyte abnormalities, because it may cause dangerous car-
diac arrhythmia and sudden cardiac death. The highest
occurrence of hyperkalaemia has been found in patients
with chronic kidney disease (73%).10 The occurrence varies
a lot between studies, mainly due to different study
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populations, but as discussed above also due to the meth-
odological challenges associated with measurements of po-
tassium levels and different limits for potassium level used
in the diagnosis of hyperkalaemia.
Important causes of increased potassium levels are given
in Table 1. The physiological increase in potassium level
during exercise has already been mentioned. A similar in-
crease in potassium level has been described as a result of
generalised muscle cramps such as in epilepsy. It may also
be seen in generalized skeletal muscle breakdown such as
rhabdomyolysis, trauma against skeletal muscles, burns,
and hyperthermia. Hyperkalaemic periodic paralysis is a
rare genetic anomaly in skeletal muscle ion channels caus-
ing depolarization of muscle cells and hyperkalaemia. In
these patients, exercise or ingestion of potassium rich
nutrients may provoke attacks of paralysis and hyperkalae-
mia that may be abated by inhalation of a b2-adrenoceptor
agonist at the beginning of the attack. Intravenous admin-
istration of potassium may increase potassium level, cause
hyperkalaemia, cardiac arrest, and sudden death. Thus, in-
travenous potassium should always be given with utmost
precaution. Oral potassium intake combined with reduced
potassium excretion may cause hyperkalaemia. Several
cardiovascular drugs—ACE-inhibitors, AT2-inhibitors, b-
adrenoceptor antagonists, aldosterone antagonists, and
digoxin—may increase potassium level. Interestingly all of
these drugs have a positive or neutral effect on life expec-
tancy in heart failure patients that may be due to a
decreased risk of hypokalaemia. Digoxin intoxication may
be associated with hyperkalaemia due to inhibition of skel-
etal muscle Na,K-pumps. Diabetes mellitus may be associ-
ated with hyperkalaemia due to lack of insulin-stimulated
Na,K-pump mediated potassium uptake in skeletal
muscles. Also, acidosis may due to reduced kidney excre-
tion of potassium cause an increase of potassium level and
hyperkalaemia. It should be noted that reduced oxidation
arising from hypoxia only induces a modest increase in
potassium level due to high affinity of the Na,K-pump for
oxygen.4,11–17
Symptoms may be relatively weak. However, hyperka-
laemiamay induce arrhythmia thatmay cause palpitations,
dizziness, syncope, and sudden cardiac death. Skeletal
muscle function may become impaired causing muscle fa-
tigue and muscle paralysis. Nevertheless, hyperkalaemia is
often detected in a routine blood sample. It may also be
detected in a routine ECG. Progressive hyperkalaemia is
typically characterized by tented or peaked Twaves, wid-
ened QRS complexes, flattened P waves, and when ex-
treme by sinus-wave appearance. Hyperkalaemia may also
cause ventricular fibrillation and cardiac arrest. The ECG
changes may erroneously mislead ECG interpretation soft-
ware to determine a two-fold increase in heart rate, and
hyperkalaemia should be considered if this phenomenon
occurs. On the other hand, if ECG is normal although potas-
sium level is high pseudohyperkalaemia should be consid-
ered. The risk of severe arrhythmia varies among various
studies in part due to themethodological challenges associ-
ated with measurements as discussed earlier. Interestingly
however, in a study on potassium levels in patients with
acute myocardial infarction it was found that in patients
with a potassium level 1mmol/L above the reference inter-
val 10% developed ventricular fibrillation or cardiac arrest
corresponding to a two-fold increase of potential fatality
as compared to patients with potassium levels in the nor-
mal range. Even more interestingly it was found that in
patients with a potassium level 1mmol/L below the refer-
ence interval 25% developed ventricular fibrillation or car-
diac arrest corresponding to a five-fold increase in
potential fatality when compared with patients with potas-
sium in the normal range. Similar observations have been
found in patients with heart failure indicating that hyper-
kalaemia should of course be feared, but hypokalaemia
should probably be feared even more. Thus, whenever ini-
tiating prophylaxis against or treatment of hyperkalaemia
precautions should be taken to avoid subsequent develop-
ment of hypokalaemia and a subsequent even higher car-
diovascular risk.18–20
Conclusions
Since determination of potassium levels may be afflicted
with various errors, potassium levels should be determined
using a standardized set-up ensuring high accuracy and pre-
cision of measurements. Potassium levels may bemeasured
as ‘plasma potassium’ or ‘serum potassium’, but these val-
ues should not be considered synonyms because serum val-
ues may be higher than plasma values. Hyperkalaemia may
be defined as a potassium level >5mmol/L, but other cut-
off levels are sometimes applied. Thus, there is a need for
establishing an international consensus in this area. Long-
term regulation of potassium homoeostasis takes place
over hours to days and depends mainly on renal potassium
excretion. Other tissues, mainly skeletal muscles, contrib-
ute to short-term regulation of potassium homoeostasis,
which takes place over seconds tominutes. Major causes of
hyperkalaemia are renal failure, exercise, epilepsy, tissue
breakdown, diabetes, and acidosis, treatment with ACE-
inhibitors, AT2-inhibitors, b-blockers, aldosterone antago-
nists, and digoxin intoxication. Hyperkalaemia may induce
impaired muscle function, ECG changes and arrhythmias
that may cause palpitations, dizziness, syncope, and sud-
den cardiac death. A decrease in potassium level by
Table 1 Important causes of increased potassium level
Renal failure
Exercise
Epilepsy
Tissue breakdown—rhabdomyolysis, trauma, hyperthermia
Hyperkalaemic periodic paralysis
Infusion of potassium. Oral potassium intake combined with
reduced potassium excretion
ACE-inhibitors, AT2-inhibitors, b-blockers, aldosterone
antagonists, and digoxin
Diabetes
Acidosis
ACE, angiotensin converting enzyme; AT2, angiotensin 2 receptor;
b-blockers, b-adrenoceptor antagonists.
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1mmol/L below the reference interval causes a 2.5-fold
higher risk of ventricular fibrillation or cardiac arrest than
an increase in potassium level by 1mmol/L above the ref-
erence interval. This indicates that of course hyperkalae-
mia should be feared, but hypokalaemia should probably
be feared even more. Thus, whenever initiating prophy-
laxis against or treatment of hyperkalaemia, precautions
should be taken to avoid subsequent development of hypo-
kalaemia and an even higher cardiovascular risk.
Conflict of interest: none declared.
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